Although there exists an apparent need to harness p53 activity to achieve normal B-cell production, there is likely a need to balance rather than abolish the activity of this protein, because loss of p53 function is a common event in human malignancies. Of special interest in the context of this report is the finding that a mutated or deleted TP53 gene is one of the strongest independent predictors of inferior treatment outcome in childhood B-lineage acute lymphoblastic leukemia. 10 In a situation where the functional dose of a transcription factor like p53 is of critical importance, the use of an autoregulatory loop such as that created by the induction of Wip1 transcription by p53 presents an elegant solution to preserve a high output of normal cells while still preventing uncontrolled malignant proliferation of progenitor cells. Therefore, the extended insight to Wip1 function provided by this report is an important contribution to our understanding of regulatory events in early B-lymphocyte development.
Conflict-of-interest disclosure: The author declares no competing financial interests. n REFERENCES TSLPR: a new CAR in the showroom for B-ALL Constructs consist of a targeting moiety such as a peptide, ligand derivative, or antibodyderived single-chain variable fragment (scFv) that is coupled in series to a hinge/spacer, membrane-spanning element, and signaling endodomain (see figure, part A). Target antigen is engaged in its native conformation, rather than as a processed peptide displayed within the groove of a human leukocyte antigen (HLA) molecule. Consequently, CARs recognize target cells irrespective of a patient's HLA haplotype. Furthermore, their function is unhindered by a common immune evasion strategy that is deployed in acute lymphoblastic leukemia (ALL) and other malignancies, namely, the selective downregulation of some HLA allo-specificities. In so-called "firstgeneration" CARs, the endodomain generally contains CD3z alone, thereby providing signals that mimic those naturally provided by the T-cell receptor/CD3 complex. Second-and third-generation receptors are distinct in that they respectively contain either 1 or 2 additional costimulatory motifs, commonly derived from CD28 and/or tumor necrosis factor receptor families. Upon target ligation, integrated signaling by the CAR endodomain results in T-cell activation and target-cell killing (see figure, part B). The provision of costimulation in latergeneration CARs ensures improved T-cell persistence in vivo, 2 a property that correlates strongly with enhanced efficacy. Target selection is of fundamental importance in maximizing the therapeutic index of CAR-based immunotherapy. Few tumor-associated antigens are truly disease specific, mandating careful risk assessment and vigilance for the emergence of "on-target, off-organ" toxicity. In B-ALL, unprecedented complete remission rates approaching 90% have been repeatedly attained in phase 1 clinical trials involving CAR T cells that engage the ubiquitous B-cell antigen, CD19. 3 Because CD19 is expressed throughout B-cell differentiation, this success occurs at the expense of predictable toxicity in the form of B-cell aplasia and hypogammaglobulinemia. Although this is clearly undesirable, it can be managed effectively with IV or subcutaneously administered immunoglobulin replacement therapy. Of greater concern, however, is the risk of therapeutic failure or relapse with CD19 null disease. 4 The latter may reflect the lack of direct contribution of CD19 expression to disease pathogenesis in B-ALL and highlights the need to identify additional candidate target molecules. Expression of the cytokine receptor-like factor 2 (CRLF2) gene may be perturbed by a number of genomic alterations in B-ALL. As a result, enhanced cell-surface expression of the encoded TSLPR protein is seen in as much as 15% of cases that lack typical chromosomal rearrangements. 5, 6 This observation raises the possibility that TSLPR could represent an attractive new candidate for CAR T-cell therapy of some patients with B-ALL. Although upregulation of TSLPR is restricted to a subset of patients, the demonstration that it can be targeted effectively using CAR-engineered T cells is important for 2 additional reasons. First, patients with B-ALL bearing CRLF2 rearrangements and TSLPR overexpression have particularly poor relapse-free and overall survival rates. 7 Second, there is significant evidence that TSLPR contributes directly to disease pathogenesis in B-ALL, a factor that may protect against antigen loss. Overexpression of TSLPR in lymphoid progenitors is sufficient to promote their growth. 5 Moreover, patient samples that express high levels of this receptor proliferate in response to TSLP, unlike samples lacking CRLF2 rearrangements. 8 However, it should be noted that leukemias in which TSLPR is upregulated also exhibit a number of cooperative genetic changes, most notably activating mutations in Janus kinase 2 (JAK2). 9 Although expression of mutated JAK2 was insufficient to enable immortalized Ba/F3 cells to grow in the absence of exogenous cytokine, 6 it has been suggested that the signaling through mutated JAK2 may be responsible for the continued, albeit slower, growth of a B-ALL cell line in which TSLPR expression had been silenced. 5 Consequently, it remains to be determined whether signaling provided by mutated JAK2 or related kinases will be sufficient to allow TSLPR loss in response to the selective pressure mediated by CAR T cells in vivo.
An additional caveat to the potential use of TSLPR as an immunotherapeutic target is the lower-level expression of this receptor in a number of other cell types, notably CD4 T cells is unknown, the potential for on-target, off-organ toxicity is of concern and warrants close attention during phase 1 clinical evaluation. The CAR tested in this study did not crossreact with the mouse ortholog of TSLPR. This contrasts with some other CARs directed against cytokine receptors and that have triggered cytokine release syndrome when evaluated in mouse xenograft models, owing to target engagement in healthy tissues. Nonetheless, the data presented suggest that TSLPR represents a promising immunotherapeutic target in a high-risk and poor-prognosis subset of B-ALL, and therefore merits further clinical development. Conflict-of-interest disclosure: The authors declare no competing financial interests. n
